Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

Alan F List1, James Vardiman, Jean-Pierre J Issa

  • 1H. Lee Moffitt Cancer Center and Research Institute, Malignant Hematology, Tampa, FL 33612-9497, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026
Same author

EZH2 and intracellular Ca<sup>2+</sup> signals interdependently coordinate alloreactive and CAR-T-cell responses.

Cellular & molecular immunology·2026
Same author

Modeling age-related methylation changes in vitro with intestinal organoids.

BMC biology·2026
Same author

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML.

HemaSphere·2025
Same author

DNA Methylation, Aging, and Cancer.

Epigenomes·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

New treatments for myelodysplastic syndromes (MDS) are emerging, driven by better understanding of MDS biology and recent FDA approvals. Tailoring therapies to disease subtypes offers hope for altering the natural course of this stem cell malignancy.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) are stem cell malignancies with evolving classification and understanding.
  • Recent FDA approval of a new therapeutic agent marks a significant advancement in MDS treatment.
  • Improved characterization of MDS natural history and biology fuels therapeutic development.

Purpose of the Study:

  • To provide an overview of recent advancements in MDS characterization and therapeutics.
  • To discuss the integration of morphologic and cytogenetic features for improved MDS classification and prognosis.
  • To highlight novel therapeutic strategies targeting MDS pathobiology.

Main Methods:

  • Review of cytogenetic abnormalities and their clinical significance.

Related Experiment Videos

  • Application of the World Health Organization (WHO) classification for MDS.
  • Exploration of targeted therapeutics including chromatin remodeling agents and anti-angiogenesis strategies.
  • Discussion of hematopoietic stem cell transplantation approaches.

    • Main Results:

    • Refined MDS classification enhances prognostic utility.
    • Targeted therapies show remarkable activity, offering potential to alter disease natural history.
    • Diverse biological processes underlying MDS necessitate tailored treatment strategies.
    • New therapeutic agents are emerging based on molecular and biological insights.

    Conclusions:

    • Advances in MDS characterization are translating into promising therapeutic options.
    • Personalized medicine approaches, tailored to MDS pathobiology, are crucial.
    • Novel therapeutics targeting chromatin structure, angiogenesis, and the microenvironment hold significant promise.
    • Hematopoietic stem cell transplantation remains a key therapeutic modality.